Characterization of Monoclonal Antibody Biosimilar through C-terminal and Disulfide Bond Peptides Sequencing Analysis on Q-TOF Mass Spectrometer

There is a significant surge in the market of biopharmaceutical products due to their popularity as alternative solution for many chronic diseases. Monoclonal antibody (mAb) is a highly complex biological macromolecule with specific therapeutic effects. It is produced from live cells in extremely complicated culture conditions. Quality control of biopharmaceuticals, especially biosimilars, is a critical step to elucidate any alteration in the primary structure as compared to the reference product (innovator). Peptide mapping and sequencing analysis of C-terminal and disulfide-bonds linked peptides are among the essential attributes for characterization of biosimilars.
In this report, characterization of a bevacizumab biosimilar is described, with focusing on peptide mapping and MS/MS sequencing of C-terminal and cysteine-containing peptides of a bevacizumab biosimilar on LCMS-9030, a Q-TOF system.

Content Type:
Document Number:
Product Type:
Liquid Chromatograph-Mass Spectrometry, Mass Spectrometry
Q-TOF, Monoclonal antibody, Biosimilar, Pharmaceutical, Life Science, LCMS-9030
File Name:
File Size:

Free Download

For Research Use Only. Not for use in diagnostic procedures.

This page may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

Top of This Page